Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 2/20 | 0.31 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.31 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | RXRB | P28702 | 1/20 | 0.31 |
| ▸ | RXRG | P48443 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25918435 | 0.88 | CYP4F2 (0.37) | CYP4F2CYP4A11DGAT2RXRARXRB | |
| SCHEMBL25917542 | 0.82 | CYP4F2 (0.34) | CYP4F2CYP4A11GAARETDGAT2 | |
| SCHEMBL30723873 | 0.80 | — | — | |
| SCHEMBL30723779 | 0.79 | NPC1 (0.33) | DGAT2 | |
| SCHEMBL25917442 | 0.78 | CYP4F2 (0.33) | CYP4F2CYP4A11 | |
| SCHEMBL30723774 | 0.75 | — | — | |
| SCHEMBL24179522 | 0.75 | RET (0.31) | CYP4F2CYP4A11RETRXRARXRB | |
| SCHEMBL30723767 | 0.75 | RET (0.31) | CYP4F2CYP4A11RETRXRARXRB | |
| SCHEMBL25918027 | 0.74 | CYP4F2 (0.33) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL30724020 | 0.73 | ALDH1A1 (0.40) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242507-A1 | INDAZOLE-FUSED CYCLIC COMPOUND | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. (CN) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242507-A1 | INDAZOLE-FUSED CYCLIC COMPOUND | SLC5A11, CYP11B2, CYP4F11 | CYP4F2 33/4885CYP4A11 4/4885GAA 2258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.